logo
  

West Pharmaceutical Services Q1 Net Income Declines; Increases 2024 Adj. EPS Guidance

West Pharmaceutical Services, Inc. (WST) reported that its first quarter net income was $115.3 million, compared to $140.0 million, prior year. Reported EPS was $1.55, declined by 16.2%. Adjusted EPS was $1.56, declined by 21.2%. On average, eight analysts polled by Thomson Reuters expected the company to report profit per share of $1.26, for the quarter. Analysts' estimates typically exclude special items.

Net sales were $695.4 million, declined 3.0%; organic net sales also declined by 3.0%. Analysts on average had estimated $670.3 million in revenue.

The company reaffirmed 2024 net sales guidance in a range of $3.000 billion to $3.025 billion. The company increased full-year 2024 adjusted EPS guidance to a new range of $7.63 to $7.88, compared to a prior range of $7.50 to $7.75. Analysts expect the company to report profit per share of $7.62.

The company also announced that its Board of Directors has approved a third-quarter 2024 dividend of $0.20 per share. The dividend will be paid on August 7, 2024, to shareholders of record as of July 31, 2024.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Comments from the Fed Chair Jerome Powell were in focus this week that also saw the release of latest inflation figures for the U.S. economy. Find out what Powell said and why those remarks underpinned investor sentiment. In Asia, Japan released first quarter GDP figures. Explore how that served to cloud the outlook for Bank of Japan interest rates. In Europe, some key figures for the U.K. labor market were released.

View More Videos
RELATED NEWS
Follow RTT